Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement-Reference-Cited by-同舟云学术

Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement

Published:2012-07 Issue:7 Volume:12 Page:550-560
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Crawford Keith W,Ripin David H Brown,Levin Andrew D,Campbell Jennifer R,Flexner Charles

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference62 articles.

1. Global HIV/AIDS response: epidemic update and health sector progress towards universal access—progress report 2011,2011

2. Exploratory study on active pharmaceutical ingredient manufacturing for essential medicines;Bumpas,2009

3. Dose optimisation: a strategy to improve tolerability and lower antiretroviral drug prices in low and middle income countries;Hill;Open Infect Dis J,2010

4. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases;Volberding;N Engl J Med,1990

5. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study;Fellay;Lancet,2001

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic Feasibility of Stability-Enhanced Solid-State (SESS) Tenofovir Disoproxil Free Base Crystal;Pharmaceutics;2023-05-01

2. Decision Criteria for Partial Nationalization of Pharmaceutical Supply Chain: A Scoping Review;Economies;2023-01-12

3. Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial;Medicine;2022-12-02

4. Transitioning Long-Acting Products to a Generic Marketplace: What's Missing?;Clinical Infectious Diseases;2022-11-21

5. Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre;Journal of Antimicrobial Chemotherapy;2022-01-18